Bruker invests in Acuity's in situ spatial genomics platform

By The Science Advisory Board staff writers

March 18, 2021 -- Acuity Spatial Genomics has announced the completion of a majority investment by Bruker.

Acuity, a Harvard Medical School spinoff, is focused on spatial 3D genomic and multiomic analysis for discovery. The genomic measurements captured through the spatial biology technology (and in the context of the transcriptome and proteome) will provide a critical understanding of the complete multiomic picture, the firm said.

The company's single-cell and accelerated super-resolution technology was designed to allow researchers to gain insights into the 3D relationships between chromosomes, gene identities, and their spatial position in the nucleus. The technology also will further insight into physical gene positioning on chromosomes, chromosome 3D conformations, chromosome and gene copy number variations, chromosomal compartments, topologically associating domains (TADs) and loops, and spatially resolved enhancer-promoter interactions.

Acuity plans to continue to commercialize the OligoFisseq and OligoFisseq high-definition technologies at the core of the in situ genome visualization platform. The platform provides insights into transcription regulatory programs that drive cell type, state, function, and pathogenesis and will help to advance knowledge in various fields of biology research.

Mark Munch, PhD, president of the Brukers Nano Group, will serve as the Acuity CEO.

Bruker revenues edge higher in Q4
Growth in Bruker's Scientific Instruments business segment and favorable currency effects helped the company to achieve a 4.6% increase in revenue in...
Preclinical lung imaging offers effective evaluation of drug candidates
Drug discovery and development are arduous and costly endeavors, with nine in 10 drug candidates failing to gain approval. Preclinical imaging can help...
Bruker launches Vutara superresolution microscope
Bruker has announced the launch of the Vutara VXL superresolution fluorescence microscope for use in nanoscale biomedical imaging.
Bruker releases MALDI-2 to advance mass spectrometry
Bruker announced a major advance in matrix-assisted laser desorption ionization (MALDI) with the launch of the world's first commercial MALDI-2 postionization...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter